You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy

Article info

Article menu

Download PDFPDF

E-Poster viewings
Ovarian Cancer
IGCS19-0608
270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
Free

Authors

Citation

Akaev I, Chau C, Dabab N, et al
270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy
International Journal of Gynecologic Cancer 2019;29:A114.

Publication history

  • First published September 18, 2019.
Online issue publication 
September 18, 2019

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.